STAR logo

Strides Pharma Science Stock Price

Symbol: NSEI:STARMarket Cap: ₹79.8bCategory: Pharmaceuticals & Biotech

STAR Share Price Performance

₹865.50
-443.75 (-33.89%)
29.1% undervalued intrinsic discount
₹1,220.00
Fair Value
₹865.50
-443.75 (-33.89%)
29.1% undervalued intrinsic discount
₹1,220.00
Fair Value
Price ₹865.50
AnalystHighTarget ₹1,220.00
AnalystConsensusTarget ₹1,078.50
AnalystLowTarget ₹937.00

STAR Community Narratives

AnalystHighTarget·Updated
Fair Value ₹1.22k 29.1% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Energize Generic Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value ₹1.08k 19.8% undervalued intrinsic discount

Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystLowTarget·Updated
Fair Value ₹937.00 7.6% undervalued intrinsic discount

US Market Dependency Will Strain Margins Yet Yield Opportunity

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent STAR News & Updates

Strides Pharma Science Limited Key Details

₹46.3b

Revenue

₹21.2b

Cost of Revenue

₹25.1b

Gross Profit

₹21.7b

Other Expenses

₹3.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
37.06
Gross Margin
54.16%
Net Profit Margin
7.38%
Debt/Equity Ratio
72.7%

Strides Pharma Science Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet, good value and pays a dividend.

2 Risks
4 Rewards

About STAR

Founded
1990
Employees
3301
CEO
Badree Komandur
WebsiteView website
www.strides.com

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.

Market Insight

Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading

Indian Market Performance

  • 7 Days: 2.4%
  • 3 Months: 1.8%
  • 1 Year: -5.1%
  • Year to Date: 0.3%
The market has climbed by 2.4% over the past week, with every sector up and the Consumer Discretionary sector leading the way. Longer term the market is actually down 5.1% over the past year. Earnings are forecast to grow by 16% annually. Market details ›